Biota, GSK Settle Relenza Marketing Suit For $19.5M
Australian drug firm Biota will receive $20 million Australian dollars ($19.46 million) from pharmaceutical giant GlaxoSmithKline over allegedly insufficient efforts to market the influenza drug Relenza....To view the full article, register now.
Already a subscriber? Click here to view full article